Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Smoking status: not checked. AREDS2 Formula: what these mean for you changes depending on whether you smoke or used to, and you have not told us. That check was skipped.
Head-to-head evidence comparison — which supplement is right for you?
AREDS2 Formula vs Liraglutide: Liraglutide has the stronger overall evidence (7.5 vs 7/10); the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Liraglutide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
One AREDS2 daily regimen, usually split into two servings: vitamin C 500 mg, vitamin E 400 IU, lutein 10 mg, zeaxanthin 2 mg, zinc 80 mg (as zinc oxide) and copper 2 mg (as cupric oxide)
With meals
A product matching the AREDS2 composition exactly: vitamin C 500 mg, vitamin E 400 IU, lutein 10 mg, zeaxanthin 2 mg, zinc 80 mg, copper 2 mg
Prescription-only, clinician-titrated, subcutaneous once daily. Diabetes (Victoza): escalate 0.6 → 1.2 → 1.8 mg/day. Weight management (Saxenda): escalate weekly to 3.0 mg/day. DO NOT self-dose.
Any time of day
Subcutaneous once-daily injection (Victoza for diabetes, Saxenda for weight)
and 3 more not shown
Years — average follow-up was 6.3 years
Years
Long-term
Years
Weeks to months
Months (titrated over weeks)
Months to years
Especially during dose escalation
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.
JAMA (2013) · Rct · n=4203
Primary analysis was NULL: lutein/zeaxanthin HR 0.90 (98.7% CI 0.76-1.07, P=.12); DHA+EPA HR 0.97 (0.82-1.16, P=.70); both together HR 0.89 (0.75-1.06, P=.10)
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.
Arch Ophthalmol (2001) · Rct · n=3640
Antioxidants plus zinc vs placebo for advanced AMD: OR 0.72 (99% CI 0.52-0.98). Zinc alone OR 0.75 (0.55-1.03); antioxidants alone OR 0.80 (0.59-1.09) — neither significant on its own
Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28.
JAMA Ophthalmol (2022) · Cohort · n=3882
10-year lung cancer odds ratio: 1.82 (95% CI 1.06-3.12, P=.02) for beta-carotene assignment vs 1.15 (0.79-1.66, P=.46) for lutein/zeaxanthin
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER).
N Engl J Med (2016) · Rct · n=9340
Double-blind cardiovascular-outcomes RCT: 9,340 patients with type 2 diabetes and high cardiovascular risk, liraglutide or placebo added to standard care, median follow-up 3.8 years.
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes).
N Engl J Med (2015) · Rct · n=3731
56-week double-blind RCT in 3,731 adults WITHOUT type 2 diabetes (BMI ≥30, or ≥27 with comorbidities), liraglutide 3.0 mg/day vs placebo plus lifestyle (2:1)
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
JAMA (2015) · Rct · n=846
56-week double-blind RCT in 846 adults with overweight or obesity and type 2 diabetes, liraglutide 3.0 mg, 1.8 mg or placebo (2:1:1), all with diet and activity advice.
Liraglutide has a higher evidence score (7.5/10 vs 7/10) and wins in 2 of 3 categories.
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.